Back to Search
Start Over
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma.
- Source :
-
European journal of haematology [Eur J Haematol] 2021 May; Vol. 106 (5), pp. 673-681. Date of Electronic Publication: 2021 Feb 16. - Publication Year :
- 2021
-
Abstract
- Objectives: To understand the impact of therapy sequencing on progression-free (PFS) and overall survival (OS) for the treatment of multiple myeloma (MM). The use of daily, low-dose, lenalidomide maintenance (LM) has raised concern for fostering resistance, preventing its use in the relapsed setting.<br />Methods: We conducted a retrospective analysis of survival outcomes from the Canadian Myeloma Research Group Database. Patients were grouped based on receipt of LM after autologous stem cell transplant and receipt of lenalidomide in second-line therapy, 575 patients were included.<br />Results: Patients treated with LM had statistically similar 2nd PFS when re-exposed to lenalidomide in second-line therapy compared to those receiving non-lenalidomide-containing regimens (10.2 vs 14.0 months, P =.53). This cohort also had the longest 2nd OS, 18 months longer than patients treated with LM who did not receive lenalidomide at relapse (55.3 vs 37 months, P =.004). Patients treated with LM also demonstrated deeper responses to second-line therapy than their non-LM counterparts.<br />Conclusion: Our data suggest that patients progressing on LM who receive lenalidomide-containing therapy at first relapse have comparable 2nd PFS and better 2nd OS compared to non-lenalidomide-containing second-line regimens. Identification of patients mostly likely to benefit from further lenalidomide-containing therapy is paramount.<br /> (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Subjects :
- Canada
Disease Management
Hematopoietic Stem Cell Transplantation
Humans
Lenalidomide administration & dosage
Maintenance Chemotherapy
Multiple Myeloma diagnosis
Multiple Myeloma mortality
Prognosis
Retrospective Studies
Treatment Outcome
Lenalidomide therapeutic use
Multiple Myeloma therapy
Preoperative Care
Subjects
Details
- Language :
- English
- ISSN :
- 1600-0609
- Volume :
- 106
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- European journal of haematology
- Publication Type :
- Academic Journal
- Accession number :
- 33539037
- Full Text :
- https://doi.org/10.1111/ejh.13596